|Dr. Hermann Lubbert Ph.D.||Exec. Chairman & Pres||18.02k||N/A||1956|
|Ms. Erica L. Monaco CPA||CEO, CFO, COO, Treasurer & Sec.||402.12k||N/A||1985|
|Ms. Erica F. Gates CPA, M.B.A.||Sr. Director of Fin. & Principal Accounting Officer||N/A||N/A||N/A|
|Mr. Daniel Hakansson J.D.||Gen. Counsel & Head of Compliance||N/A||N/A||N/A|
|Mr. Mark Baldyga||Head of Sales & Marketing||N/A||N/A||N/A|
|Mr. Jeff Holm||Head of Professional Relations & Commercial Devel.||N/A||N/A||N/A|
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.